Merus N.V. announced on December 16, 2024, that the first patient has been dosed in its Phase 2 trial evaluating petosemtamab monotherapy. This trial focuses on heavily pretreated (3L+) metastatic colorectal cancer (mCRC) patients.
Petosemtamab, a Biclonics® targeting EGFR and LGR5, will be assessed for safety and antitumor activity in patients post anti-EGFR therapy who lack specific KRAS and NRAS mutations. Preclinical studies have shown petosemtamab to have superior activity compared to cetuximab in CRC models.
This expansion of petosemtamab's clinical development into mCRC represents a strategic move to address unmet needs in another difficult-to-treat cancer type. It highlights Merus's commitment to exploring the full potential of its multispecific antibody platform.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.